Nedosiran - Latest Advances

The oxalobiome: unraveling the role of gut microbiota in oxalate metabolism and its implications for kidney health and disease management.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: December 17, 2025

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Journal: Frontiers in pharmacology

Published: October 07, 2025

Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies.

Journal: Kidney international

Published: July 29, 2025

Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1.

Journal: Clinical pharmacokinetics

Published: June 05, 2025

RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: April 07, 2025

Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation.

Journal: Kidney & blood pressure research

Published: March 09, 2025

Development, opportunities, and challenges of siRNA nucleic acid drugs.

Journal: Molecular therapy. Nucleic acids

Published: February 03, 2025

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

Journal: Kidney international reports

Published: December 20, 2024

Concomitant Treatment With Lumasiran and Nedosiran in a Child With Primary Hyperoxaluria Type 1.

Journal: Kidney international reports

Published: December 02, 2024

Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study.

Journal: Orphanet journal of rare diseases

Published: October 15, 2024

Comparison of Three Computational Tools for the Prediction of RNA Tertiary Structures.

Journal: Non-coding RNA

Published: October 03, 2024

Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).

Journal: Pediatric nephrology (Berlin, Germany)

Published: September 24, 2024